July 08, 2026
Why Antimicrobial Resistance is a Growing Threat
Antimicrobial resistance (AMR) is one of the greatest public health challenges of our time. According to the Council of Canadian Academies 2026 report, an estimated one in four bacterial infections in Canada are resistant to first-line drugs, directly causing approximately 5,400 deaths each year.
When bacteria become resistant to antibiotics, common infections become harder to treat, hospital stays become longer and healthcare costs increase.
Why Speed Matters
One of the biggest challenges in fighting AMR is speed.
Today, determining whether a bacterium is resistant to antibiotics often requires growing it in a laboratory, a process that can take days. During that time, patients may receive ineffective treatments while healthcare providers wait for results.
How Genomics Can Help
Vancouver-based biotechnology company BugSeq is working to change that.
BugSeq is an automated, cloud-based bioinformatics platform that enables clinical laboratories to rapidly identify and characterize pathogens and outbreaks in their healthcare systems. With support from Genome BC, BugSeq is improving their genomic tools that can rapidly identify pathogens and predict antimicrobial resistance directly from DNA sequencing data, paving the way for rapid and comprehensive genomic pathogen characterization in clinical laboratories. Their cloud-based platform helps clinical and public health laboratories analyze complex genomic information quickly and accurately, improving predictions of antimicrobial resistance
At the heart of this work is BugAMR, BugSeq’s machine learning-powered antimicrobial resistance prediction system.
Taking The Next Step
Genome BC funding is helping BugSeq take the next step by improving prediction accuracy. Researchers will analyze nearly 100,000 bacterial genomes, identify new resistance markers and incorporate additional genetic features that may improve resistant prediction performance. The project will also use artificial intelligence to rapidly review scientific literature and include newly discovered resistance markers, that haven’t yet been added to public AMR databases.
The enhanced system will be validated through both computational testing and real-world clinical studies with partners including local BC hospitals and other world-leading clinical sites. Clinical sites including Vancouver Coastal Health, Providence Health Care and Johns Hopkins University have published using AMR prediction functionality within BugSeq and will see benefit from this innovation.
“Partnering with Genome BC is an important step for us,” said Nick Gauthier, Head of Scientific Affairs at BugSeq. “By refining our machine-learning analytics with Genome BC’s support, we can dramatically scale our database and enhance the performance of our tools. This collaboration bridges the gap between cutting-edge genomic research and real-world clinical utility, ultimately allowing us to put faster, life-saving insights directly into the hands of healthcare providers when every hour counts.”
Preparing Canada Proactively for AMR and Beyond
Beyond improving patient care, BugSeq’s platform is helping strengthen Canada’s public health preparedness.
Through a separate Genome BC and Genome Canada-supported initiative, BugSeq’s co-developed end-to-end metagenomic sequencing workflow is being deployed within public health laboratories across Canada to evaluate its use for detecting respiratory diseases and emerging variants. Conventional diagnostic tests require clinicians to know which pathogen to target in advance, whereas this method is pathogen-agnostic; strengthening the capacity of Canadian laboratories to respond to emerging biothreats.
Together, these projects highlight the important role genomics can play in addressing urgent healthcare challenges. By supporting innovative BC companies like BugSeq, Genome BC is helping accelerate the development of tools that improve patient outcomes, strengthen public health systems and build resilience against future infectious disease threats.
